|Bid||39.05 x 800|
|Ask||39.08 x 1100|
|Day's Range||38.71 - 39.04|
|52 Week Range||37.43 - 50.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||1.86 (4.64%)|
|1y Target Est||47.67|
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent ® (dupilumab) improved moderate-to-severe asthma Results ...
* In steroid-sparing VENTURE trial, Dupixent-treated patients substantially reduced use of oral corticosteroids, yet had fewer exacerbations and improved lung function compared to placebo. * Results showed ...
Moody's Investors Service, ("Moody's") has today assigned a first-time B3 corporate family rating (CFR) and a B3-PD Probability of Default Rating (PDR) to Al Sirona (Luxembourg) Acquisition S.a.r.l. ...
Canada is about to become the first major industrialized nation to legalize marijuana use across the country, and the companies that have positioned themselves to profit could see remarkable gains
President Trump took heat for being too soft on drug companies in a speech last week. The Centers for Medicare and Medicaid Services on Tuesday, May 15, rolled out revamped Drug Spending Dashboards that likely will put pressure on drug companies to lower prices. The newly designed dashboards show how much is spent in Medicare Part B, Medicare Part D and Medicaid for name-brand drugs.
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
AstraZeneca’s (AZN) Cardiovascular and Metabolic Disease (or CVMD) segment includes various products such as Brilinta, Farxiga, Bydureon, Byetta, Onglyza, and Symlin and legacy products such as Atacand, Crestor, and Seloken.
PARIS and TARRYTOWN, N.Y., May 16, 2018 /PRNewswire/ -- A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints. Dupixent is the first and only biologic to show positive results in this patient population. "Moderate-to-severe atopic dermatitis can place a particularly significant burden on adolescents, who have to deal with oozing skin lesions with unrelenting, intense itching during their formative years," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron.
LONDON, UK / ACCESSWIRE / May 16, 2018 / If you want access to our free research report on Sanofi American Depositary Shares (NYSE: SNY) ("Sanofi"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SNY as the Company's latest news hit the wire. On May 14, 2018, the Company along with Ablynx NV (NASDAQ: ABLX) together reported the successful results of the initial tender offer period of Sanofi's previously announced tender offers to acquire all of the outstanding shares, including shares represented by American Depositary Shares (ADSs), warrants, and convertible bonds of Ablynx.
A year ago LVMH, the owner of luxury brand Louis Vuitton, became France’s biggest company by market value, a mantle energy giant Total SA and drugmaker Sanofi SA had shared for almost a decade. Kering SA was nowhere in sight. A more than 200 percent rally since the start of 2016, and more than 70 percent over the past 12 months, has now put the owner of “it bag” brands within shouting distance of the top five stocks in the CAC 40 Index.
May 16, 2018 - A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints. Dupixent is the first and only biologic to show positive results in this patient population. "Moderate-to-severe atopic dermatitis can place a particularly significant burden on adolescents, who have to deal with oozing skin lesions with unrelenting, intense itching during their formative years," said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron.
Genzyme recently cut 95 jobs in Framingham, while TJX and Staples, both headquartered in the city, have slashed a combined 477 workers in undisclosed locations.
Launching today, Scratch Beneath the Surface is a new UK public health initiative created by Sanofi in collaboration with leading national charity, Allergy UK. By improving awareness of atopic dermatitis, Scratch Beneath the Surface hopes to shift any misconceptions among the general public and combat the stigma related to the disease, which will in turn, lead to those affected feeling a greater sense of support and understanding.
The marijuana market in North America is growing at an astounding rate, with investors who are in the know set to reap most of the rewards
Investors pursuing a solid, dependable stock investment can often be led to Sanofi (NYSE:SNY), a large-cap worth US$94.36B. Doing business globally, large caps tend to have diversified revenue streams andRead More...
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period ...
Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.
Warren Buffett is widely recognized as the greatest investor in the world, based on a decades-long record of outperformance, but he's the first to acknowledge that he's merely mortal, with more than his share of mistakes. The Oracle of Omaha announced in 2018 that Berkshire Hathaway completely exited its IBM position.
In 1Q18, Amgen’s (AMGN) Repatha revenue grew 15% YoY (year-over-year) to $123 million from $49 million, primarily due to higher unit demand. It grew ~26% quarter-over-quarter. In US and international markets, Repatha generated revenue of $84 million and $39 million, respectively, compared with $33 million and $16 million in 1Q17.
On April 30, the FDA granted priority review status to the sBLA (supplemental biologics license application) seeking approval for the combination of Merck’s (MRK) Keytruda, Eli Lilly’s (LLY) Alimta, and platinum-based chemotherapy agents like carboplatin or cisplatin in first-line metastatic NSCLC (non-squamous non-small cell lung cancer) indication. The Prescription Drug User Fee Act’s date is September 23. The sBLA is based on data from the Phase 3 KEYNOTE-189 trial declared on April 16. ...
In 1Q18, Amgen’s (AMGN) Nplate revenue grew 16% YoY (year-over-year) to $179 million from $154 million, primarily driven by unit demand. It grew ~8% QoQ (quarter-over-quarter).
Measuring Sanofi’s (ENXTPA:SAN) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations, whichRead More...